Healthcare may not have been in the emergency room, or even the ICU, during 2011, but this sector was sick from beginning to end. Unfortunately, the story that was true in 2010 is still true today - higher unemployment means fewer people with health insurance, and even those with coverage are more nervous about taking time off or meeting their copays. At the same time, hospitals and the federal government continue to draw hard lines on pricing, and there have been few innovative product launches to stimulate new markets.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Just to frame the discussion, the Dow Jones U.S. Medical Devices Index Fund (NYSE:IHI) has fallen more than 5% year-to-date as of this writing.

A Very Familiar Name on Top
Yet again, one name dominated the list of top-performing med-techs. Intuitive Surgical (Nasdaq:ISRG) is still really the only game in town when it comes to surgical robots, and demand for these devices has remained high despite a fairly conservative environment for hospital equipment. Intuitive has seen revenue rise nearly 30% over the trailing twelve months, while the stock has jumped nearly 70%. Trading at over 23 times EBITDA and nearly 10 times revenue, this is hardly an undiscovered bargain in the space, but it does offer the growth that institutional investors are so desperate to find. (For related reading, see A Primer On The Biotech Sector.)

Interestingly enough, the next two best performers are two of the largest companies in the sector and are often derided and lamented for their unimpressive growth potential. Abbott Labs (NYSE:ABT) has risen more than 17% this year, helped by good stent, diagnostics and drug sales, as well as investor approbation for its plans to split the business. Giant Johnson & Johnson (NYSE:JNJ) is also a market-beater this year (up about 7%) as a renaissance in the prescription drug business offsets poor performance in devices, diagnostics and consumer health.

To find more examples of large med-tech names that are likely to end the year in the green requires a bit of stretching the meaning of both "large" and "med-tech". Vision care specialist Cooper (NYSE:COO) has delivered almost 20% gains this year, while veterinary lab company IDEXX (Nasdaq:IDXX) and dental products company Dentsply (Nasdaq:XRAY) have delivered single-digit gains.

And that's pretty much it when it comes to the success stories.

Plenty of Names in the Red
By comparison, it takes scarcely no work at all to find familiar med-tech names that have lost money for shareholders in 2011. Virtually the entire categories of cardiac rhythm management and orthopedics are in the red this year, as government investigations over reimbursement and concerns about proper patient identification weigh on the sector. Medtronic (NYSE:MDT) is the least-bad with a 4% retracement, while St. Jude (NYSE:STJ) has fallen 20% and Boston Scientific (NYSE:BSX) has dropped 30%. Likewise, Stryker (NYSE:SYK), Zimmer (NYSE:ZMH) and Smith & Nephew (NYSE:SNN) all dropped by mid-teen percentages.

Along the way, a host of other names have delivered modestly disappointing performance this year. Baxter (NYSE:BAX), Bard (NYSE:BCR) and Covidien (NYSE:COV) are all modestly in the red for 2011, even though the performance at Baxter and Covidien hasn't been all that bad.

The Bottom Line
Will 2012 be a year of recovery in this sector? On the plus side, this year's poor performance has left many names like Stryker, St. Jude, Medtronic and Covidien attractively priced for patient long-term investors. That said, there is no reason to expect a great rebound in sales or profits until employment picks up and government pressures on reimbursement and regulatory approval ease up. (For related reading, see Investing In The Healthcare Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Stephen Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Chart Advisor

    Now Could Be The Time To Buy IPOs

    There has been lots of hype around the IPO market lately. We'll take a look at whether now is the time to buy.
  2. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  3. Chart Advisor

    Copper Continues Its Descent

    Copper prices have been under pressure lately and based on these charts it doesn't seem that it will reverse any time soon.
  4. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  5. Mutual Funds & ETFs

    Buying Vanguard Mutual Funds Vs. ETFs

    Learn about the differences between Vanguard's mutual fund and ETF products, and discover which may be more appropriate for investors.
  6. Mutual Funds & ETFs

    ETFs Vs. Mutual Funds: Choosing For Your Retirement

    Learn about the difference between using mutual funds versus ETFs for retirement, including which investment strategies and goals are best served by each.
  7. Mutual Funds & ETFs

    How to Reinvest Dividends from ETFs

    Learn about reinvesting ETF dividends, including the benefits and drawbacks of dividend reinvestment plans (DRIPs) and manual reinvestment.
  8. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  9. Mutual Funds & ETFs

    Best 3 Vanguard Funds that Track the Top 500 Companies

    Discover the three Vanguard funds tracking the S&P 500 Index, and learn about the characteristics and historical statistics of these funds.
  10. Forex Fundamentals

    How to Buy Chinese Yuan

    Discover the different options that are available to investors who want to obtain exposure to the Chinese yuan, including ETFs and ETNs.
  1. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  2. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  3. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
  4. Are Vanguard ETFs commission-free?

    While some Vanguard exchange-traded funds (ETFs) are available commission-free from third-party brokers, a large portion ... Read Full Answer >>
  5. Do Vanguard ETFs require a minimum investment?

    Vanguard completely waives any U.S. dollar minimum amounts to buy its exchange-traded funds (ETFs), and the minimum ETF investment ... Read Full Answer >>
  6. Can mutual fund expense ratios be negative?

    Mutual fund expense ratios cannot be negative. An expense ratio is the sum total of all fees charged by an asset management ... Read Full Answer >>

You May Also Like

Trading Center